Literature DB >> 24129424

[O'Dell reloaded: Do we use TNF inhibitors too early?].

K Krüger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24129424     DOI： 10.1007/s00393-013-1269-8

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  7 in total

1.  Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.

Authors:  Ronald F van Vollenhoven; Pierre Geborek; Kristina Forslind; Kristina Albertsson; Sofia Ernestam; Ingemar F Petersson; Katerina Chatzidionysiou; Johan Bratt
Journal:  Lancet       Date:  2012-03-29       Impact factor: 79.321

2.  Trends in treatment strategies and the usage of different disease-modifying anti-rheumatic drugs in early rheumatoid arthritis in Finland. Results from a nationwide register in 2000-2007.

Authors:  V Rantalaiho; H Kautiainen; L Virta; M Korpela; T Möttönen; K Puolakka
Journal:  Scand J Rheumatol       Date:  2010-08-20       Impact factor: 3.641

3.  [German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm].

Authors:  K Krüger; J Wollenhaupt; K Albrecht; R Alten; M Backhaus; C Baerwald; W Bolten; J Braun; H Burkhardt; G Burmester; M Gaubitz; A Gause; E Gromnica-Ihle; H Kellner; J Kuipers; A Krause; H-M Lorenz; B Manger; H Nüßlein; H-G Pott; A Rubbert-Roth; M Schneider; C Specker; H Schulze-Koops; H-P Tony; S Wassenberg; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2012-09       Impact factor: 1.372

4.  A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.

Authors:  Larry W Moreland; James R O'Dell; Harold E Paulus; Jeffrey R Curtis; Joan M Bathon; E William St Clair; S Louis Bridges; Jie Zhang; Theresa McVie; George Howard; Désirée van der Heijde; Stacey S Cofield
Journal:  Arthritis Rheum       Date:  2012-09

Review 5.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maxime Dougados; Paul Emery; Cecile Gaujoux-Viala; Simone Gorter; Rachel Knevel; Jackie Nam; Monika Schoels; Daniel Aletaha; Maya Buch; Laure Gossec; Tom Huizinga; Johannes W J W Bijlsma; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Cem Gabay; Juan Gomez-Reino; Marios Kouloumas; Tore K Kvien; Emilio Martin-Mola; Iain McInnes; Karel Pavelka; Piet van Riel; Marieke Scholte; David L Scott; Tuulikki Sokka; Guido Valesini; Ronald van Vollenhoven; Kevin L Winthrop; John Wong; Angela Zink; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

6.  A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.

Authors:  L Heimans; K V C Wevers-de Boer; K Visser; R J Goekoop; M van Oosterhout; J B Harbers; C Bijkerk; I Speyer; M P D M de Buck; P B J de Sonnaville; B A M Grillet; T W J Huizinga; C F Allaart
Journal:  Ann Rheum Dis       Date:  2013-05-28       Impact factor: 19.103

7.  Therapies for active rheumatoid arthritis after methotrexate failure.

Authors:  James R O'Dell; Ted R Mikuls; Thomas H Taylor; Vandana Ahluwalia; Mary Brophy; Stuart R Warren; Robert A Lew; Amy C Cannella; Gary Kunkel; Ciaran S Phibbs; Aslam H Anis; Sarah Leatherman; Edward Keystone
Journal:  N Engl J Med       Date:  2013-06-11       Impact factor: 91.245
  7 in total
  1 in total

1.  [Clinical remission in rheumatoid arthritis. Data from the early arthritis cohort study CAPEA].

Authors:  K Albrecht; J Callhoff; E Edelmann; G Schett; M Schneider; A Zink
Journal:  Z Rheumatol       Date:  2016-02       Impact factor: 1.372
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.